Bausch + Lomb Corporation Stock Price, News & Analysis

Bausch + Lomb (NYSE/TSX: BLCO), a global eye health company, has scheduled two important investor events. The company will release its second-quarter 2025 financial results on Wednesday, July 30, 2025, at 8:00 a.m. ET, followed by a conference call and live webcast to discuss results and provide a business update.

Additionally, Bausch + Lomb will host an investor day on Thursday, November 13, 2025, where it plans to present a business update and showcase its innovative product pipeline. Further details about the investor day will be provided closer to the event date.

Bausch + Lomb (NYSE/TSX: BLCO) has successfully completed several significant financing transactions. The company closed an upsized offering of €675 million senior secured floating rate notes due 2031 and executed a partial credit agreement refinancing including a $2.325 billion term B loan facility and an $800 million revolving credit facility.

The notes will bear interest at three-month EURIBOR plus 3.875% per year with a 0% floor. The term B loans carry an interest rate of 4.25% for SOFR Loans and 3.25% for ABR Loans. The proceeds were used to refinance existing debt facilities and pay related expenses.

Bausch + Lomb announced the pricing of an upsized €675 million senior secured floating rate notes offering due 2031, increased from the initially planned €600 million. The Notes will be sold at 99.500% of principal value. The company is also seeking to obtain a $2.325 billion new term B loan facility (increased from $2.2 billion) with Term SOFR + 4.25% interest rate, and an $800 million revolving credit facility. The proceeds will be used to repay existing revolving credit facility borrowings, refinance term A and B loans due 2027, and cover related expenses. The Notes will be guaranteed by the company and its subsidiary guarantors, secured by first priority liens. Both the Notes offering and new credit facilities are expected to close on June 26, 2025.

Bausch + Lomb (NYSE/TSX: BLCO) has announced a significant refinancing initiative involving multiple components. The company's subsidiaries are launching a €600 million senior secured floating rate notes offering. Additionally, BLCO is seeking to establish a new $2.2 billion term B loan facility and an $800 million revolving credit facility. The proceeds will be used to refinance existing debt, including repaying outstanding revolving credit facility borrowings and refinancing term A and B loans due 2027. The notes will be guaranteed by the company and its subsidiary guarantors, secured by first-priority liens on assets that secure the company's credit agreement obligations. The offering is limited to qualified institutional buyers in the US under Rule 144A and non-US persons under Regulation S, with Canadian sales restricted to exempt transactions.

Bausch + Lomb (NYSE/TSX: BLCO) has launched two new preservative-free lubricating eye drops in the United States: Blink Nourish and Blink Boost. Blink Nourish, priced at $15.99 for 10mL, is the first vitamin-enriched preservative-free eye drop containing vitamin B12, vitamin C, magnesium, and amino acids, designed to replenish the tear film. The formula includes hyaluronan and trehalose for tear film stability. Blink Boost, priced at $13.99 for 10mL, features a pH-balanced formula matching healthy tears and contains hyaluronan, electrolytes, and antioxidants. Both products are contact-lens friendly and available at major U.S. retailers including Walmart, Target, CVS, Walgreens, and Amazon.

Bausch + Lomb (NYSE/TSX: BLCO) announced that CFO Sam Eldessouky will participate in the 2025 Jefferies Global Healthcare Conference. The presentation is scheduled for June 4, 2025, at 7:35 a.m. ET in New York City. Investors can access a live webcast of the conference through the company's Investor Relations website. Bausch + Lomb is a global eye health company focused on helping people improve their vision and quality of life.

Bausch + Lomb (NYSE/TSX: BLCO) held its 2025 Annual Meeting of Shareholders on May 21, 2025, where shareholders elected all 10 nominated directors to the board. The meeting resulted in strong approval rates for all nominees, with each director receiving over 337 million votes in favor.

Additionally, shareholders approved several other key measures including: a non-binding advisory vote on executive compensation, the appointment of PricewaterhouseCoopers LLP as the company's auditor until the 2026 Annual Meeting, and authorization for the board to determine the auditor's remuneration.

Bausch + Lomb (NYSE/TSX: BLCO) has launched LUMIFY Preservative Free redness reliever eye drops in the United States, marking a significant expansion of their eye care product line. The new product is the first and only preservative-free over-the-counter eye drops containing low-dose brimonidine tartrate 0.025%. The drops provide relief from eye redness due to minor irritations within 60 seconds, targeting consumers with sensitive eyes. The original LUMIFY, launched in 2018, has garnered over 50,000 five-star reviews. Unlike traditional redness relievers, LUMIFY products selectively target eye redness with a lower risk of rebound redness and efficacy loss. LUMIFY Preservative Free is now available at major U.S. retailers including Walmart, Target, CVS, Walgreens, Rite Aid, and Amazon, with a suggested retail price of $26.99.

Bausch + Lomb (NYSE/TSX: BLCO) has launched Zenlens CHROMA HOA scleral contact lenses in the United States. This innovative product is designed to correct advanced higher-order aberrations (HOA) using custom, wavefront-guided scleral lens technology. The lenses utilize proprietary technologies including SmartCurve™ and Bi-Elevation™ to achieve secure lens fit and reduce visual distortions.

The company is partnering with Advance Medical and OVITZ® for implementation, utilizing Advance Medical's FocalPoints® software platform for manufacturing and OVITZ's xwave aberrometer for measurement. The technology aims to enhance vision quality and improve clarity by reducing symptoms such as halos and glare, particularly benefiting patients with complex corneal irregularities.